Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>23andMe's recent earnings report reveals a period of significant transition and strategic refocus for the company, characterized by financial adjustments, business restructuring, and an evolving operational strategy.</li><li>These developments present a nuanced view of the company's current state and future potential in the health genetics and consumer genomics sector.</li><li>On the positive side, 23andMe reported strides in its overarching goal to achieve cash-flow positivity.</li></ul>

23andMe's recent earnings report reveals a period of significant transition and strategic refocus for the company, characterized by financial adjustments, business restructuring, and an evolving operational strategy.These developments present a nuanced view of the company's current state and future potential in the health genetics and consumer genomics sector.On the positive side, 23andMe reported strides in its overarching goal to achieve cash-flow positivity.

23andMe On The Brink? Exploring a Potential Sale Amid Financial Struggles!

<ul><li>23andMe, the renowned genetic testing and health data company, has recently garnered significant attention with its co-founder and CEO, Anne Wojcicki, expressing openness to considering third-party acquisition offers.</li><li>This comes on the heels of her ongoing efforts to take the company private, despite the board’s rejection of her initial proposal.</li><li>With a combination of promising proprietary assets and a shaky financial trajectory, 23andMe finds itself at a crossroads.</li></ul>

23andMe, the renowned genetic testing and health data company, has recently garnered significant attention with its co-founder and CEO, Anne Wojcicki, expressing openness to considering third-party acquisition offers.This comes on the heels of her ongoing efforts to take the company private, despite the board’s rejection of her initial proposal.With a combination of promising proprietary assets and a shaky financial trajectory, 23andMe finds itself at a crossroads.

Inside the 23andMe Buyout Rumors: Will Anne Wojcicki Take the Company Private?

SPAC Deep Dive, subSPAC

subSPAC

SPAC Deep Dive

Each week we’ll identify and break down for you SPACs that are capturing market share and making an impact.

Thematic (Sector/Industry)

<ul><li>The last week of SPACs was packed with market activity including deals, IPOs, and Lawsuits.</li><li>The  SPAC bubble burst has led to the market being flooded with penny stocks.</li><li>Also, a serial sponsor upsizes its IPO for its next SPAC, a SPAC is taking a drug development firm public, and a medical testing firm comes under scrutiny due to mounting losses and lawsuits from customers.</li></ul>

The last week of SPACs was packed with market activity including deals, IPOs, and Lawsuits.The  SPAC bubble burst has led to the market being flooded with penny stocks.Also, a serial sponsor upsizes its IPO for its next SPAC, a SPAC is taking a drug development firm public, and a medical testing firm comes under scrutiny due to mounting losses and lawsuits from customers.

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>SPACs - remember them? US offerings in 2021 topped ~US$150bn, falling to US$13bn in 2022. Singapore joined the bandwagon in January 2022  and Hong Kong two months later.</li>
<li>That Hong Kong stock is <strong><a href="https://www.smartkarma.com/entities/aquila-acquisition-corporation" target="_blank" data-smartkarma-citation="entities:35435:1" rel="noopener">Aquila Acquisition Corporation (7836 HK)</a></strong>, and it recently announced a merger with <strong>ZG Group</strong>, a Chinese steel trading website.</li>
<li>That's positive. Less positive is how de-SPACed shares tend to trade in the US. </li>
</ul>


SPACs - remember them? US offerings in 2021 topped ~US$150bn, falling to US$13bn in 2022. Singapore joined the bandwagon in January 2022  and Hong Kong two months later.
That Hong Kong stock is Aquila Acquisition Corporation (7836 HK), and it recently announced a merger with ZG Group, a Chinese steel trading website.
That's positive. Less positive is how de-SPACed shares tend to trade in the US. 


United States

23andMe Holding Co. operates as a consumer genetics and research company. The Company provides direct-to-consumer genetic testing services. 23andMe Holding serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

23andMe Holding Co (ME US)

23andMe On The Brink? Exploring a Potential Sale Amid Financial Struggles!

23andMe's recent earnings report reveals a period of significant transition and strategic refocus for the company, characterized by financial...

Baptista Research

Inside the 23andMe Buyout Rumors: Will Anne Wojcicki Take the Company Private?

23andMe, the renowned genetic testing and health data company, has recently garnered significant attention with its co-founder and CEO, Anne...

Baptista Research

The Penny Drop

The last week of SPACs was packed with market activity including deals, IPOs, and Lawsuits. The SPAC bubble burst has led to the market being...

subSPAC

Aquila Acquisition: The De-SPACed Arb

The gross spread to the redemption price is 4.8%. I'd be redeeming. Shares are beyond illiquid. Unless shares were to dip here, on some volume,...

David Blennerhassett

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)